Normal view MARC view ISBD view

Id Boufker, Hichame

The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. [electronic resource] - BMC cancer Jun 2010 - 298 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

ISSN: 1471-2407

Standard No.: 10.1186/1471-2407-10-298 doi

Subjects--Topical Terms:
Adolescent
Adult
Alkaline Phosphatase--metabolism
Ascorbic Acid--pharmacology
Bone Marrow Cells--drug effects
Calcification, Physiologic--drug effects
Cell Differentiation--drug effects
Cell Proliferation--drug effects
Cell Separation
Cells, Cultured
Child
Child, Preschool
Dasatinib
Dexamethasone--pharmacology
Dose-Response Relationship, Drug
Extracellular Matrix--drug effects
Gene Expression Regulation--drug effects
Glycerophosphates--pharmacology
Humans
Integrin-Binding Sialoprotein
Kinetics
Mesenchymal Stem Cells--drug effects
Middle Aged
Osteoblasts--drug effects
Osteogenesis--drug effects
Osteopontin--metabolism
Phosphorylation
Protein Kinase Inhibitors--pharmacology
Proto-Oncogene Mas
Pyrimidines--pharmacology
RANK Ligand--metabolism
Sialoglycoproteins--metabolism
Thiazoles--pharmacology
Young Adult
src-Family Kinases--antagonists & inhibitors